Table 1. SOX2 expression in relation to clinicopathological characteristics in CRC.
| SOX2 negative | SOX2 positive | p valuea | |
| Frequencies, n (%) | 394 (89.3) | 47 (10.7) | |
| Sex, n (%) | 0.032 | ||
| Male | 224 (92.2) | 19 (7.8) | |
| Female | 170 (85.9) | 28 (14.1) | |
| Age, n (%) | 0.548 | ||
| ≤59 years | 70 (86.4) | 11 (13.6) | |
| 60–69 years | 97 (90.7) | 10 (9.3) | |
| 70–79 years | 147 (91.3) | 14 (8.7) | |
| ≥80 years | 80 (87.0) | 12 (13.0) | |
| TNM stage, n (%) b | 0.034 | ||
| I | 62 (93.9) | 4 (6.1) | |
| II | 153 (92.2) | 13 (7.8) | |
| III | 81 (89.0) | 10 (11.0) | |
| IV | 87 (82.1) | 19 (17.9) | |
| Localization, n (%) b | 0.283 | ||
| Right colon | 122 (85.9) | 20 (14.1) | |
| Left colon | 118 (90.1) | 13 (9.9) | |
| Rectum | 149 (91.4) | 14 (8.6) | |
| Grade, n (%) b | 0.004 | ||
| Highly to moderately differentiated | 202 (93.5) | 14 (6.5) | |
| Moderately to poorly differentiated | 185 (84.9) | 33 (15.1) | |
| MSI screening status, n (%) b | 0.725 | ||
| MSI | 60 (88.2) | 8 (11.8) | |
| MSS | 321 (89.7) | 37 (10.3) | |
| CIMP status, n (%) b | 0.193 | ||
| CIMP-negativec | 198 (91.7) | 18 (8.3) | |
| CIMP-lowc | 145 (87.9) | 20 (12.1) | |
| CIMP-highc | 47 (83.9) | 9 (16.1) | |
| BRAFV600E , n (%) b | <0.001 | ||
| wild type | 339 (91.4) | 32 (8.6) | |
| mutated | 47 (75.8) | 15 (24.2) | |
| KRAS (codon 12, 13), n (%) b | 0.928 | ||
| wild type | 315 (89.2) | 38 (10.8) | |
| mutated | 72 (88.9) | 9 (11.1) |
Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; CIMP, CpG island methylator phenotype (according to an eight-gene CIMP panel).
a
χ2 test.
b
The following numbers of missing cases were present: TNM stage, 12; localization, 5; grade, 7; MSI screening status, 15; CIMP status, 4; BRAF V600E, 8; KRAS, 7.
c
CIMP negative, no promoter hypermethylation; CIMP low, one to five genes methylated; CIMP high, six to eight genes methylated.